PTH Peptide Freeze-Drying Oxidation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The challenge in producing freeze-dried preparations of PTH peptide is the formation of PTH analogs due to exposure to air environments in pharmaceutical production facilities, leading to impurities that cannot be controlled, especially as production scale increases, affecting the purity and safety of the final product.
Innovation Solution
Controlling the exposure of PTH peptide solutions to air environments within pharmaceutical production facilities by using a controlled air flow and inert gas purging to minimize the production of PTH analogs, ensuring high-purity freeze-dried preparations by maintaining low levels of oxidizing substances like ozone and formaldehyde, and using specific handling techniques such as sub-door management during loading into freeze-drying chambers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PTH peptide solution is exposed to air environment in pharmaceutical production facility, then sterilization and aseptic environment are maintained, but PTH analogs are formed due to oxidation, reducing product purity
Solution Approach 1:
The patent applies inert atmosphere by replacing air with nitrogen gas in the production environment. Specifically, the facility is filled with nitrogen to maintain an oxygen-free atmosphere during PTH peptide processing, preventing oxidation of methionine and tryptophan residues that would otherwise form PTH analogs. This resolves the contradiction by maintaining a controlled environment that protects the peptide from oxidative degradation while still allowing for proper sterilization and handling.
2Productivity
If production scale is increased, then productivity improves, but control over PTH analog formation becomes difficult, affecting product quality
Solution Approach 1:
The patent applies parameter changes by fundamentally altering the chemical environment parameters - specifically reducing oxygen concentration to near-zero levels and controlling humidity and temperature. By changing these environmental parameters to create an inert atmosphere, the patent enables large-scale production while maintaining consistent control over PTH analog formation, as the oxidative reaction pathway is effectively eliminated regardless of production volume.
3Ease of manufacture
If oxidizing substances like ozone and formaldehyde are present for sterilization, then disinfection is effective, but PTH peptide undergoes oxidation, forming unwanted analogs
Solution Approach 1:
The patent applies preliminary action by performing sterilization and disinfection procedures before introducing the PTH peptide into the production environment. The facility is thoroughly sterilized with appropriate agents, then completely dried and purged with nitrogen to remove all oxidizing residues before peptide processing begins. This sequence ensures effective sterilization while preventing subsequent oxidation of the peptide during manufacturing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly reduces the levels of PTH analogs, ensuring high-purity PTH peptide preparations by minimizing exposure to oxidizing agents, thereby enhancing the safety and efficacy of the pharmaceutical product.
Implementation Method 1
Controlling the exposure of PTH peptide solutions to air environments within pharmaceutical production facilities by using a controlled air flow and inert gas purging to minimize the production of PTH analogs
Implementation Method 2
Freeze-dried preparation containing high-purity PTH and method for producing same
Data Source
Figure 1
Figure 2
Figure 3
AI summary
[Problem] Provided is a freeze-dried preparation containing high-purity PTH peptide and a method for the production thereof. Also provided is a test method for PTH analogs to confirm the purity of a freeze-dried preparation containing PTH peptide, and the like. [Solution] In the present invention, the presence of PTH analogs produced during the manufacturing process of a freeze-dried preparation containing PTH peptide was confirmed. The production of these PTH analogs was also discovered to be markedly prevented or reduced by controlling exposure of the solution containing PTH peptide and the like to air environments within a pharmaceutical production facility.